Tenaya Therapeutics, Inc. SEC filings TNYA
Tenaya Therapeutics, Inc. has 353 filings in SEC EDGAR's recent list, going back to May 7, 2021. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 27, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| EFFECT | Filing | Aug 17, 2022 | — |
| CORRESP | Letter to the SEC | Aug 15, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2022 | — |
| SEC STAFF LETTER | Filing | Aug 2, 2021 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| CERT | Filing | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 27, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| 8-A12B | Filing | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2021 | — |
| DRS/A | Filing | Jun 16, 2021 | — |
| DRSLTR | Filing | Jun 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 10, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| DRS | Filing | May 7, 2021 | — |
Showing 24 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TNYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858848
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.